**SUPPLEMENTARY ONLINE INFORMATION TO 'EFFECTS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS ON RATING SCALE-ASSESSED SUICIDALIDTY IN DEPRESSED ADULTS' BY NÄSLUND *ET AL.***

*This document encompasses one supplementary figure and three supplementary tables, as well as the corresponding figure and table legends*

**Legend to supplementary figure**

*Online figure DS1:* Baseline rating of suicidality, as well as effects of treatment on the rating of suicidality at end-point and at the last-available observation for adults (≥25 years of age) and young adults (18-24 years of age), respectively. ES=effect size.

**Legends to supplementary tables**

*Online table DS1: No. (% placebo) =* number of patients (% of which received placebo) with a baseline HDRS evaluation. *No HDRS data week 6 (4)* = Percentage of patients lacking data at the last week included in the analysis (week 6 or week 4) due to drop-out or other reason. Age and baseline HDRS-17 sum score are given as means ± standard deviation. CIT = citalopram, FLX = fluoxetine, PRX = paroxetine, SER = sertraline, PLA = placebo.

*Online table DS2: Depressed mood* = rating of the depressed mood item of HDRS at the first occasion of suicidal emergency. *HDRS-17-sum =* sum rating of all HDRS-17 items at the first occasion of suicidal emergency. SEM = standard error of the mean.

*Online table DS3: Depressed mood* = rating of the depressed mood item of HDRS at the first occasion of suicidal emergency. *HDRS-17-sum =* sum rating of all HDRS-17 items at the first occasion of suicidal emergency. SEM = standard error of the mean.

**SUPPLEMENTARY MATERIAL***Online table DS1: Study characteristics*

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Trial** | **Treatment** **groups** | **No.** **(%** **placebo)** | **Females** | **% age** **18-24** | **Mean age** | **Mean** **HDRS-17****sum score** **at baseline** | **Duration** | **No HDRS** **data week 6 (4)** | **No HDRS** **data** **week 1-2** |
| GSK/001 | PRX, PLA | 50 (50%) | 70% | 6% | 43.4±12.3 | 24.9±3.4 | 6 weeks | 92% | 4% |
| GSK/002 | PRX, PLA | 341 (50%) | 48% | 6% | 41.5±12.2 | 23.8±3.9 | 6 weeks | 44% | 5% |
| GSK/003 | PRX, PLA | 485 (50%) | 48% | 6% | 40.4±11.6 | 23.6±3.6 | 6 weeks | 50% | 4% |
| GSK/009 | PRX, PLA | 474 (11%) | 49% | 5% | 41.0±12.9 | 22.6±3.2 | 6 weeks | 38% | 5% |
| GSK/115 | PRX, FLX, PLA | 688 (17%) | 34% | 6% | 41.5±11.8 | 22.4±3.7 | 12 weeks | 29% | 5% |
| GSK/128 | PRX, FLX, PLA | 848 (17%) | 37% | 7% | 41.2±12.2 | 23±3.8 | 12 weeks | 28% | 3% |
| GSK/251 | PRX, PLA | 254 (51%) | 34% | 6% | 41.3±10.9 | 22.1±3.4 | 8 weeks | 29% | 4% |
| GSK/274 | PRX, PLA | 45 (51%) | 29% | 11% | 42.5±12.4 | 23.2±3.0 | 4 weeks | 29% | 9% |
| GSK/276 | PRX, PLA | 41 (51%) | 44% | 7% | 44.2±12-6 | 24.4±5.0 | 6 weeks | 59% | 0% |
| GSK/279 | PRX, PLA | 31 (32%) | 29% | 19% | 44.3±18.4 | 21.1±3.7 | 6 weeks | 52% | 6% |
| GSK/448 | PRX, PLA | 315 (33%) | 37% | 8% | 39.0±10.5 | 23.2±2.8 | 12 weeks | 23% | 3% |
| GSK/449 | PRX, PLA | 333 (33%) | 33% | 7% | 41.1±11.6 | 23.7±3.2 | 12 weeks | 19% | 2% |
| GSK/487 | PRX, PLA | 323 (34%) | 43% | 0% | 69.9±6.0 | 22.2±3.2 | 12 weeks | 17% | 3% |
| GSK/810 | PRX, PLA | 454 (33%) | 41% | 12% | 38.8±11.6 | 23.5±3.1 | 8 weeks | 18% | 4% |
| GSK/874 | PRX, PLA | 521 (35%) | 39% | 0% | 67.3±6.4 | 22.8±3.8 | 10 weeks | 14% | 2% |
| LB/85A | CIT, PLA | 180 (51%) | 67% | 4% | 43.0±13.6 | 24.0±3.4 | 4 weeks | 45% | 6% |
| LB/89303 | CIT, PLA | 200 (33%) | 31% | 8% | 43.2±13.6 | 23.8±6.3 | 6 weeks | 27% | 4% |
| LB/91206 | CIT, PLA | 650 (20%) | 40% | 10% | 38.6±10.7 | 21.9±3.3 | 6 weeks | 32% | 9% |
| PZ/101 | SER, PLA | 122 (21%) | 66% | 7% | 42.7±12.4 | 26.6±6.2 | 4 weeks | 46% | 2% |
| PZ/103 | SER, PLA | 369 (25%) | 47% | 8% | 37.6±10.3 | 25.1±3.0 | 6 weeks | 46% | 7% |
| PZ/104 | SER, PLA | 300 (50%) | 47% | 8% | 39.6±11.6 | 23.4±3.8 | 8 weeks | 33% | 6% |
| PZ/109 | SER, PLA | 210 (50%) | 38% | 7% | 41.3±11.3 | 21.7±3.4 | 8 weeks | 33% | 1% |
| PZ/111 | SER, FLX, PLA | 335 (33%) | 31% | 7% | 41.0±12.2 | 24.3±2.2 | 8 weeks | 33% | 5% |
| PZ/238 | SER, PLA | 199 (20%) | 30% | 7% | 37.6±9.8 | 21.7±3.7 | 10 weeks | 34% | 6% |
| PZ/240 | SER, PLA | 70 (50%) | 44% | 0% | 69.7±5.4 | 23.6±3.8 | 10 weeks | 44% | 1% |
| PZ/247 | SER, PLA | 85 (49%) | 40% | 0% | 69.5±5.3 | 24.1±3.8 | 10 weeks | 46% | 1% |
| PZ/310 | SER, PLA | 174 (20%) | 28% | 5% | 50.1±13.4 | 24.3±5.4 | 4 weeks | 25% | 1% |
| PZ/315 | SER, PLA | 165 (48%) | 28% | 12% | 42.2±12.5 | 22.7±4.4 | 8 weeks | 38% | 15% |

*Online table DS2: Adults (≥25years of age)*

|  |
| --- |
| **Depression severity in patients with emergent suicidality**  |
|  | *Definition of emergency*  | *Treatment* | *n* | *Mean (SEM)* | *p* |
| *Depressed mood* | Loose | PLA | 212 | 2.78 (0.05) | .24 |
|  | SSRI | 303 | 2.69 (0.05) |  |
| Strict | PLA | 31 | 3.16 (0.11) | .21 |
|  | SSRI | 51 | 2.92 (0.13) |  |
| *HDRS-17-sum* | Loose | PLA | 212 | 22.8 (0.37) | .90 |
|  | SSRI | 303 | 22.7 (0.32) |  |
| Strict | PLA | 31 | 24.9 (0.79) | .91 |
|  | SSRI | 51 | 24.8 (0.86) |  |

*Online table DS3: Young adults (18-24 years of age)*

|  |
| --- |
| **Depression severity in patients with emergent suicidality**  |
|  | *Definition of emergency*  | *Treatment* | *n* | *Mean (SEM)* | *p* |
| *Depressed mood* | Loose | PLA | 7 | 2.14 (0.34) | .31 |
|  | SSRI | 34 | 2.56 (0.17) |  |
| Strict | PLA | 2 | 2.00 (1.00) | .54 |
|  | SSRI | 6 | 2.67 (0.49) |  |
| *HDRS-17-sum* | Loose | PLA | 7 | 21.7 (2.02) | .97 |
|  | SSRI | 34 | 21.6 (0.82) |  |
| Strict | PLA | 2 | 21.5 (10.5) | .94 |
|  | SSRI | 6 | 22.0 (2.02) |  |

*Online figure DS1*

